肝内胆管细胞癌的临床病理学观察

朱珍; 丛文铭

肝内胆管细胞癌的临床病理学观察

朱珍,
丛文铭

第二军医大学东方肝胆外科医院病理科

详细信息

中图分类号: R735.8
计量
- 文章访问数: 3921
- HTML全文浏览量: 18
- PDF下载量: 789
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Clinicopathological study of intrahepatic bile duct cancers from 1982 to 2011

摘要

摘要:
常见肝内胆管恶性肿瘤有肝内胆管癌(ICC)、细胆管细胞癌(CLC)及混合细胞型肝癌(CHC)中的胆管癌成分。ICC是肝脏第二常见恶性肿瘤,根据我院手术切除的3.3万余例肝脏恶性肿瘤的病理资料统计,肝细胞癌(HCC)和ICC分别占85.6%和7.7%,ICC的发病呈逐年上升趋势,具有易转移复发的生物学特性;CLC少见,因起源于肝脏双向分化的前体细胞而具有侵袭性强的特点;CHC的病理检出率有增多趋势,预后较HCC和ICC更差。准确的病理分型对于临床诊治和预后评估具有实际意义。
- 胆管肿瘤 /
- 病理学,临床
Abstract:
Based on tumor histogenesis, intrahepatic bile duct cancers can be classified as intrahepatic cholangiocarcinoma (ICC) , cholangiocellular carcinoma (CLC) , or combined hepatocellular-cholangiocarcinoma (CHC) .ICC is the second most common hepatic malignant tumor type, after hepatocellular carcinoma (HCC) .Pathological analysis of more than 33 000 malignant liver tumors surgically resected from patients in our hospital between January 1982 and December 2011 revealed that HCC and ICC types accounted for 85.6% and 7.7%, respectively.In addition, clinicopathological analyses of these tumors and patient cases revealed an annual increase in incidence of ICC that was accompanied by similar positive trends in metastasis and recurrence.CLC cases were rare, but generally characterized as aggressive and originating from bipotential hepatic progenitor cells.For CHC tumors, there was an increasing trend for the pathological detection rates, but the prognosis of CHC cases remained worse than that for either HCC or ICC.The accumulated data of our institute's cases of intrahepatic bile duct cancers over the past 30 years indicate that pathological classification has important clinical implications for treatment and outcome.
- bile duct neoplasms /
- pathology

HTML全文

参考文献(20)

[1]丛文铭, 吴孟超.肝内胆管癌的微卫星不稳定性和杂合性缺失特点[J].中华肿瘤杂志, 2002, 24 (2) :141.

[2]丛文铭, 吴孟超.肝癌基因组不稳定性的研究现状与展望[J].第二军医大学学报, 2002, 23 (1) :5-9.

[3]周福平, 胡和平, 艾建华, 等.运用激光捕获显微切割对肝细胞癌与肝内胆管癌蛋白质组的分析[J].第二军医大学学报, 2005, 26 (10) :1111-1115.

[4]Kobayashi M, Ikeda K, Saitoh S, et al.Incidence of primarycholangiocellular carcinoma of the liver in japanese patients withhepatitis C virus-related cirrhosis[J].Cancer, 2000, 88 (11) :2471-2477.

[5]俞文隆, 张永杰, 董辉, 等.肝门部胆管癌的病理生物学特点及其临床意义的研究[J].中华外科杂志, 2009, 47 (15) :1162-1166.

[6]Varnholt H, Vauthey JN, Dal Cin P.Biliary adenofibroma:arare neoplasm of bile duct origin with an indolent behavior[J].Am J Surg Pathol, 2003, 27 (5) :693-698.

[7]Borbath I, Verbrugghe L, Lai R, et al.Human equilibrative nu-cleoside transporter 1 (hENT1) expression is a potential predic-tive tool for response to gemcitabine in patients with advancedcholangiocarcinoma[J].Eur J Cancer, 2012, 48 (7) :990-996.

[8]Mitsuo S, Sugimoto J, Iwahashi S, et al.CD133 expressionis a potential prognostic indicator in intrahepatic cholangiocar-cinoma[J].J Gastroenterol, 2010, 45 (8) :896-902.

[9]Higashi M, Yamada N, Yokoyama S, et al.Pathobiologicalimplications of MUC16/CA125 expression in intrahepaticcholangiocarcinoma-mass forming type[J].Pathobiology, 2012, 79 (2) :101-106.

[10]Min JK, Kim JM, Li SJ.L1 cell adhesion molecule is a noveltherapeutic target in intrahepatic cholangiocarcinoma[J].Clin Cancer Res, 2010, 16 (14) :3571-3580.

[11]Nakanuma Y, Sripa B, Vatanasapt V.Intrahepatic cholangiocar-cinoma.In:Hamilton SR, Aaltonen LA, eds.WHO classifica-tion of tumors, pathology and genetics of tumours of the diges-tive system[M].Lyon:IARC Press, 2000:173-180.

[12]Komuta M, Spee B, Vander Borght S, et al.Clinicopathologicalstudy on cholangiolocellular carcinoma suggesting hepatic pro-genitor cell origin[J].Hepatology, 2008, 47 (5) :1544-1556.

[13]Theise ND, Nakashima O, Park YN, et al.In:Bosman FT, Carneiro F, Hruban RH, Theise ND, editors.World healthorganization classification of tumors.WHO classification oftumors of the digestive system[M].Lyon:International A-gency for Research on Cancer, 2010:225-227.

[14]Kanamoto M, Yoshizumi T, Ikegami T.Cholangiolocellular car-cinoma containing hepatocellular carcinoma and cholangiocel-lular carcinoma, extremely rare tumor of the liver:a case re-port[J].J Med Invest, 2008, 55 (1-2) :161-165.

[15]Lu XY, Xi T, Lau WY, et al.Hepatocellular carcinoma ex-pressing cholangiocyte phenotype is a novel subtype withhighly aggressive behavior[J].Ann Surg Oncol, 2011, 18 (8) :2210-2217.

[16]Zhang F, Chen XP, Zhang W, et al.Combined hepatocellularcholangiocarcinoma originating from hepatic progenitor cells:im-munohistochemical and double-fluorescence immunostainingevidence[J].Histopathology, 2008, 52 (2) :224-232.

[17]Zen C, Zen Y, Mitry RR, et al.Mixed phenotype hepatocellularcarcinoma after transarterial chemoembolization and liver trans-plantation[J].Liver Transplantation, 2011, 17 (8) :943-954.

[18]Jarnagin WR, Weber S, Tickoo SK.Combined hepatocellularand cholangiocareinoma:demographic, clinical, and prog-nostic factors[J].Cancer, 2002, 94 (7) :2040-2046.

[19] Ariizumi SI, Kotera Y, Katagiri S, et al.Combined hepatocel-lular-cholangiocarcinoma had poor outcomes after hepatec-tomy regardless of Allen and Lisa class or the predominanceof intrahepatic vholangiocarcinoma cells within the Tumor[J].Ann Surg Oncol, 2012, 19 (5) :1628-1636.

[20]Kim JH, Yoon HK, Ko GY, et al.Nonresectable combined hepato-cellular carcinoma and cholangiocarcinoma:analysis of the re-sponse and prognostic factors after transcatheter arterial chemo-embolization[J].Radiology, 2010, 255 (1) :270-278.

施引文献

资源附件(0)

访问统计